Methemoglobinemia screening: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
[[Methemoglobinemia]] screening is not routinely done. | |||
==Screening== | ==Screening== | ||
Revision as of 13:57, 15 May 2018
|
Methemoglobinemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Methemoglobinemia screening On the Web |
|
American Roentgen Ray Society Images of Methemoglobinemia screening |
|
Risk calculators and risk factors for Methemoglobinemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Aksiniya K. Stevasarova, M.D.
Overview
Methemoglobinemia screening is not routinely done.
Screening
Currently in the United States the newborn screening for G6PD is not routinely done. It is performed only in neonates presenting with jaundice. [1]
Currently we have a screening test for G6PD deficiency that has been tested in Thai population, since G6PD is very common in this pateint population. It is called methemoglobin reduction test (MRT), it is not expensive and it uses cord blood of neonates to check for the enzyme deficiency. Even though it has low sensitivity around 65%, it does have acceptable specificity arounf 90%. [2]
Referrences
- ↑ "PMID: 10916676" Baillieres Best Pract Res Clin Haematol. 2000 Mar;13(1):21-38. Glucose-6-phosphate dehydrogenase deficiency. Mehta A1, Mason PJ, Vulliamy TJ.
- ↑ "pmid11529386" J Med Assoc Thai. 2001 Jun;84 Suppl 1:S91-8. The value of methemoglobin reduction test as a screening test for neonatal glucose 6-phosphate dehydrogenase deficiency. Sanpavat S1, Nuchprayoon I, Kittikalayawong A, Ungbumnet W.